Clinical Pharmacology · Antiarrhythmic Medications
Calcium Channel Blockers for Arrhythmias
On this page 6 sections
In 30 seconds
Class IV antiarrhythmics are the non-dihydropyridine calcium channel blockers verapamil and diltiazem. They slow the sinus node and, more importantly, prolong conduction and refractoriness through the AV node, making them workhorse drugs for rate control in atrial fibrillation and flutter and for terminating AV-nodal reentrant tachycardia. Dihydropyridines like amlodipine have no antiarrhythmic role because they act almost exclusively on vascular smooth muscle. Their major hazards are excessive AV blockade, negative inotropy, and pre-excited atrial fibrillation.
The college version
Why only two calcium channel blockers matter here
Calcium channel blockers split into dihydropyridines (amlodipine, nifedipine) and non-dihydropyridines (verapamil, diltiazem). Both block L-type channels but differ in tissue selectivity. Dihydropyridines bind preferentially to vascular smooth muscle, producing vasodilation with little cardiac electrical effect — useful as antihypertensives but irrelevant for rhythm control. Verapamil and diltiazem act substantially on the SA and AV nodes, which is why only these two earn a place in Vaughan Williams Class IV.
The electrophysiology
Most myocardium depolarizes rapidly through fast sodium channels. The SA and AV nodes differ: their upstroke depends on slow, calcium-mediated depolarization through L-type channels rather than sodium influx. Verapamil and diltiazem modestly slow SA nodal firing, but their dominant effect is on the AV node: slowing conduction velocity and prolonging refractoriness. Fewer atrial impulses reach the ventricles per unit time, and reentrant circuits using the AV node as one limb can be interrupted.
Clinical uses
The most common use is ventricular rate control in atrial fibrillation and flutter, where the atria fire chaotically or rapidly and AV nodal conduction determines how many impulses reach the ventricles; slowing it improves symptoms without fixing the atrial rhythm itself. Verapamil and diltiazem also terminate AV-nodal reentrant tachycardia, a paroxysmal SVT circulating through the AV node, when vagal maneuvers and adenosine are contraindicated, unsuccessful, or inappropriate. A third use is multifocal atrial tachycardia, an irregular rhythm from multiple competing atrial foci often seen with severe pulmonary disease; slowing AV conduction reduces the rapid, irregular ventricular response.
Cautions and contraindications
These drugs are meaningful negative inotropes, a poor choice in heart failure with reduced ejection fraction, where depressing contractility can worsen decompensation. Combining them with a beta blocker is dangerous: both classes independently slow AV conduction and depress the SA node, risking profound bradycardia or AV block. They are contraindicated in wide-complex tachycardia of uncertain origin, since if the rhythm is actually ventricular tachycardia, blocking calcium channels can cause collapse without treating it. They are likewise contraindicated in pre-excited atrial fibrillation, as in Wolff-Parkinson-White syndrome: an accessory pathway bypasses the AV node, so blocking it removes its protective gatekeeping and can accelerate conduction down that pathway, risking ventricular fibrillation. Additional concerns include hypotension, constipation (especially with verapamil), and a digoxin interaction: verapamil raises digoxin levels, compounding AV nodal suppression.
A note on classification
Adenosine is often used alongside these drugs for AV-nodal reentrant tachycardia, but it is not a calcium channel blocker and fits nowhere in the Vaughan Williams classification. It acts through adenosine receptors to transiently and profoundly block the AV node, its ultra-short duration setting it apart from Class IV drugs.

Eli explains
The same idea, in plain words
Explain it like I’m 10
Picture the AV node as a narrow tollbooth between the heart's top and bottom chambers: when the top chambers fire signals way too fast, like in atrial fibrillation, the tollbooth decides how many reach the bottom chambers. Verapamil and diltiazem make the tollbooth close more slowly and stay closed longer, so fewer cars get through and the bottom chambers beat calmer. Dihydropyridines don't touch the tollbooth — they just relax blood vessel "roads," so they're useless here. But there's a catch: if a secret side road skips the tollbooth, slowing the tollbooth pushes more traffic onto that unguarded road, which is dangerous. And if the heart's pump is already weak, or a beta blocker is added too, the gate can jam almost shut.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A patient with Wolff-Parkinson-White syndrome presents in pre-excited, irregular atrial fibrillation. Explain why giving verapamil would be dangerous.
Show answer
Blocking the AV node removes its protective gatekeeping, letting more impulses race down the accessory pathway.
In Wolff-Parkinson-White, a hidden side road skips the AV node tollbooth. Verapamil only slows the tollbooth, so signals reroute onto the unguarded road even faster, risking a life-threatening ventricular rhythm.
A patient with heart failure with reduced ejection fraction needs rate control for atrial fibrillation. Explain why a clinician would be cautious about verapamil or diltiazem.
Show answer
Verapamil and diltiazem reduce the heart's pumping force, which can worsen an already weak heart.
Both drugs are negative inotropes, making the heart squeeze less forcefully. In a heart already struggling to pump, adding a drug that weakens the squeeze further can tip the patient into worse heart failure.
Quick check
3 questions here. Answers stay hidden until you check.
What is the primary mechanism by which verapamil and diltiazem control ventricular rate in atrial fibrillation?
Which combination poses the greatest risk of profound bradycardia or AV block?
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.

